---
title: "aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292765672.md"
description: "aTyr Pharma will present a subgroup analysis of the Phase 3 EFZO-FIT™ study on Efzofitimod for pulmonary sarcoidosis at the WASOG 2026 conference. This presentation highlights specific participant subsets to provide detailed insights into the drug's efficacy and performance in treating the condition."
datetime: "2026-07-15T12:02:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292765672.md)
  - [en](https://longbridge.com/en/news/292765672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292765672.md)
---

# aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma will be showcasing a subgroup analysis of the Phase 3 EFZO-FIT™ study of Efzofitimod in pulmonary sarcoidosis at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) conference in 2026. The study is paramount in evaluating the efficacy of Efzofitimod. This analysis will focus on specific subsets of participants, shedding light on the drug's impact. This event is significant as it provides detailed insights from the trial and aids in understanding the drug's performance in treating pulmonary sarcoidosis.

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [60 Degrees Pharma hits minimum enrollment trigger for interim readout in severe babesiosis tafenoquine trial](https://longbridge.com/en/news/294254910.md)
- [MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophrenia](https://longbridge.com/en/news/293920685.md)
- [Fortress Biotech subsidiary Urica says Crystalys closes $130 million Series B financing](https://longbridge.com/en/news/293929289.md)
- [Kazia Therapeutics files provisional patent for strategy to prevent metastatic recurrence in triple-negative breast cancer](https://longbridge.com/en/news/294058325.md)
- [AUO: 2Q26 saw revenue growth and a return to profit, but Display segment weakness persists](https://longbridge.com/en/news/294308310.md)